Florian Heitz

10.8k total citations
180 papers, 3.2k citations indexed

About

Florian Heitz is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Florian Heitz has authored 180 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Reproductive Medicine, 65 papers in Oncology and 55 papers in Obstetrics and Gynecology. Recurrent topics in Florian Heitz's work include Ovarian cancer diagnosis and treatment (125 papers), Endometrial and Cervical Cancer Treatments (48 papers) and PARP inhibition in cancer therapy (37 papers). Florian Heitz is often cited by papers focused on Ovarian cancer diagnosis and treatment (125 papers), Endometrial and Cervical Cancer Treatments (48 papers) and PARP inhibition in cancer therapy (37 papers). Florian Heitz collaborates with scholars based in Germany, France and Belgium. Florian Heitz's co-authors include Andreas du Bois, Philipp Harter, Alexander Traut, Beyhan Ataseven, Sonia Prader, Christoph Grimm, Sandro Pignata, Sabrina Chiara Cecere, Ignace Vergote and Christian Kurzeder and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Florian Heitz

168 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Florian Heitz Germany 33 1.9k 1.1k 1.0k 894 540 180 3.2k
Karin Leunen Belgium 33 1.7k 0.9× 997 0.9× 859 0.9× 1.2k 1.3× 335 0.6× 114 3.2k
Anne Floquet France 30 1.2k 0.7× 1.3k 1.2× 665 0.7× 808 0.9× 758 1.4× 170 3.3k
Edgar Petru Austria 33 1.5k 0.8× 1.5k 1.3× 749 0.7× 1.2k 1.3× 898 1.7× 222 3.9k
Floor Backes United States 32 1.6k 0.9× 895 0.8× 648 0.6× 1.7k 1.9× 381 0.7× 179 3.4k
Jean Hurteau United States 29 1.3k 0.7× 1.1k 1.0× 657 0.7× 664 0.7× 328 0.6× 90 3.2k
Philippe Moerman Belgium 31 1.3k 0.7× 772 0.7× 459 0.5× 1.9k 2.1× 592 1.1× 125 3.6k
Tomoyasu Kato Japan 27 802 0.4× 611 0.6× 543 0.5× 973 1.1× 369 0.7× 194 2.9k
Christine Walsh United States 30 1.0k 0.5× 874 0.8× 282 0.3× 687 0.8× 349 0.6× 93 2.6k
Yoo-Young Lee South Korea 32 748 0.4× 630 0.6× 1.1k 1.1× 1.2k 1.4× 288 0.5× 158 3.0k
Beyhan Ataseven Germany 29 752 0.4× 935 0.8× 593 0.6× 468 0.5× 367 0.7× 124 2.3k

Countries citing papers authored by Florian Heitz

Since Specialization
Citations

This map shows the geographic impact of Florian Heitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florian Heitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florian Heitz more than expected).

Fields of papers citing papers by Florian Heitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florian Heitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florian Heitz. The network helps show where Florian Heitz may publish in the future.

Co-authorship network of co-authors of Florian Heitz

This figure shows the co-authorship network connecting the top 25 collaborators of Florian Heitz. A scholar is included among the top collaborators of Florian Heitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florian Heitz. Florian Heitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wimberger, Pauline, Jacobus Pfisterer, Andreas du Bois, et al.. (2025). Impact of lymphadenectomy rates in the quality assurance program in early ovarian cancer of the AGO Study Group – Real-world observations. European Journal of Surgical Oncology. 51(6). 109696–109696.
2.
Hattesohl, Akira, Julia Teply‐Szymanski, Florian Heitz, et al.. (2024). Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer—Development of Recommendations for Optimal Assay Performance. Modern Pathology. 37(4). 100445–100445. 5 indexed citations
3.
4.
Tsibulak, Irina, Stephanie Schneider, Alexander Traut, et al.. (2023). #644 Surgical management of FIGO stage IV epithelial ovarian cancer versus FIGO stage IIIC: the real-world experience from KEM. A37–A38. 1 indexed citations
5.
Wimberger, Pauline, Jacobus Pfisterer, Andreas du Bois, et al.. (2023). Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study Group. International Journal of Gynecological Cancer. 33(7). 1083–1089. 6 indexed citations
6.
Heitz, Florian, Christian Marth, Stéphanie Henry, et al.. (2023). AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial. International Journal of Gynecological Cancer. 33(12). 1966–1969. 11 indexed citations
7.
8.
Grube, Marcel, Cor D. de Kroon, Fabienne Schochter, et al.. (2022). 2022-RA-894-ESGO Endometrioid ovarian carcinoma – real world evidence from a large transatlantic team initiative: First results of the LEOPARD study. International Journal of Gynecological Cancer. 32. A275–A275. 1 indexed citations
9.
Ataseven, Beyhan, et al.. (2022). 2022-RA-778-ESGO Rare gynecological cancers in a gynecologic cancer center: 11-year experience of KEM. International Journal of Gynecological Cancer. 32. A189–A190. 1 indexed citations
10.
11.
Krämer, Bernhard, Elena Ioana Braicu, Bastian Czogalla, et al.. (2022). Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT database. Archives of Gynecology and Obstetrics. 307(4). 1155–1162. 3 indexed citations
12.
Bizzarri, Nicolò, Robert Fruscio, Anna Myriam Perrone, et al.. (2022). Impact of substage and histologic type in stage I ovarian carcinoma survival: a multicenter retrospective observational study. International Journal of Gynecological Cancer. 33(1). 42–49. 2 indexed citations
13.
Labidi‐Galy, Sana Intidhar, Manuel Rodrigues, José Luís Sandoval, et al.. (2022). Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis. Annals of Oncology. 34(2). 152–162. 27 indexed citations
14.
Braicu, Elena Ioana, Andreas du Bois, Jalid Sehouli, et al.. (2021). Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring. Cancers. 14(1). 168–168. 8 indexed citations
15.
Kulbe, Hagen, Oliver Klein, Eliane T. Taube, et al.. (2020). Discovery of Prognostic Markers for Early-Stage High-Grade Serous Ovarian Cancer by Maldi-Imaging. Cancers. 12(8). 2000–2000. 13 indexed citations
16.
Prader, Sonia, Andreas du Bois, Florian Heitz, et al.. (2018). Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer. Gynecologic Oncology. 152(1). 76–81. 27 indexed citations
17.
Winterhoff, Boris, Stefan Kommoss, Florian Heitz, et al.. (2018). Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions.. eScholarship (California Digital Library). 2018. 1093–1102. 5 indexed citations
18.
Bois, Andreas du, Fabian Trillsch, Sven� Mahner, Florian Heitz, & Philipp Harter. (2016). Management of borderline ovarian tumors. Annals of Oncology. 27. i20–i22. 58 indexed citations
19.
Harter, Philipp, Pier Francesco Alesina, Dietmar Lorenz, et al.. (2014). Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. Gynecologic Oncology. 132(3). 537–541. 33 indexed citations
20.
Frédy, D, Florian Heitz, Didier Mathieu, & N Vasile. (1989). [Tolerability of a new non-ionic contrast medium, iopromide in x-ray computed tomography. Comparison with ioxaglate 320 mgI/ml].. PubMed. 32(4 Pt 2). 358–60. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karin Leunen Breakdown of academic impact, for papers by Anne Floquet Breakdown of academic impact, for papers by Edgar Petru Breakdown of academic impact, for papers by Floor Backes Breakdown of academic impact, for papers by Jean Hurteau Breakdown of academic impact, for papers by Philippe Moerman Breakdown of academic impact, for papers by Tomoyasu Kato Breakdown of academic impact, for papers by Christine Walsh Breakdown of academic impact, for papers by Yoo-Young Lee Breakdown of academic impact, for papers by Beyhan Ataseven
Rankless by CCL
2026